Orchid Pharma

Orchid Pharma Limited submitted its monitoring agency report for the quarter ended September 30, 2025, regarding the utilization of Rs. 400 crore raised through Qualified Institutional Placement. The company revised the allocation of QIP proceeds among project objectives following shareholder approval through AGM resolution dated September 20, 2025. Two key projects face implementation delays: the investment in Orchid BioPharma Limited for setting up manufacturing facility in Jammu, and funding capital expenditure for new API facility block in Alathur, Tamil Nadu, though the extent of delays remains unascertainable. For the Jammu project, Rs. 73.02 crores has been utilized as of September 30, 2025, with land acquisition challenges cited as the primary cause of delay. Registration of 164.50 Kanal out of 203.8 Kanal identified land has been completed, with remaining land registration expected by December 2025. The Alathur project delay is attributed to dependency on the Jammu 7ACA project, with only Rs. 0.36 crores utilized. The company has deployed unutilized proceeds in fixed deposits with Yes Bank Limited. CARE Ratings Limited served as the monitoring agency and reported no deviation from stated objectives.

Orchid Pharma is targeting capacity expansion and new product launches across Cephalosporin and Carbapenem APIs. The company projects FY26 revenue growth of 13% year-on-year. A new plant in Chennai is being commissioned to enhance API output by 25%. The company is focusing on export market penetration and backward integration. The R&D pipeline includes 8 new molecules. Orchid Pharma expects volume-led growth and higher EBITDA margins in FY26-27.

Orchid Pharma Limited announced its quarterly results for the quarter ended September 30, 2025. The company reported standalone net sales of Rs 193.52 crores compared to Rs 172.93 crores in the previous quarter, marking growth in revenue. The company achieved a standalone profit before tax of Rs 20.23 crores for the current quarter versus Rs 204.29 crores in the previous quarter. Basic earnings per share stood at Rs 0.44 for the quarter. The company completed acquisitions of 100% assets of Alectra Therapeutics GmbH, Germany and Alectra Therapeutics SAS, France, gaining global ownership of Enmetazobactam antibiotic molecule. Orchid Pharma also acquired 100% share capital of Weichensee 1272 VV GmbH, Germany, now renamed as Orchid Pharma Europe GmbH. The Board of Directors approved the unaudited financial results in a meeting held on November 11, 2025. The company has submitted a petition for amalgamation with its holding company Dhanuka Laboratories Limited to the National Company Law Tribunal, Chennai bench.